|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 5,827,721: Gene Therapy for Cardiovascular Disease
United States Patent 5,827,721, titled "Gene therapy for cardiovascular disease," issued on October 27, 1998, to The Johns Hopkins University. The patent claims methods for treating cardiovascular disease by introducing genetic material into cardiac cells. The underlying technology involves the delivery of genes encoding beneficial proteins, such as vascular endothelial growth factor (VEGF), to promote angiogenesis and improve blood flow in ischemic cardiac tissue.
What is the core innovation claimed by US Patent 5,827,721?
The patent's core innovation lies in the method of treating cardiovascular disease through the introduction of specific genetic material into cardiac cells. This genetic material is designed to express therapeutic proteins that counteract the effects of the disease.
Claim 1, a representative independent claim, describes a method for treating a cardiovascular disease in a subject, comprising the step of introducing into cardiac cells of the subject a nucleic acid molecule encoding a therapeutic protein that promotes blood vessel growth. The patent defines cardiovascular disease broadly to include conditions such as myocardial infarction, angina, congestive heart failure, and peripheral vascular disease. The therapeutic proteins contemplated include growth factors, cytokines, and enzymes that can stimulate angiogenesis or protect cardiac tissue from damage.
What are the key claimed methods and compositions?
The patent encompasses several key claimed methods and compositions related to gene therapy for cardiovascular conditions.
Claimed Methods
- Gene Introduction for Angiogenesis: The patent claims methods for treating cardiovascular disease by delivering nucleic acid molecules encoding proteins that promote blood vessel growth. This is central to addressing ischemic conditions where blood flow is compromised.
- Delivery Vectors: While not exclusively limited to specific vectors, the claims contemplate the use of various means for introducing the genetic material into cardiac cells. This includes viral vectors (e.g., adenoviruses, retroviruses) and non-viral methods (e.g., liposomes, direct injection).
- Targeting Cardiac Cells: The methods are directed towards introducing the genetic material specifically into cardiac cells, such as cardiomyocytes and vascular endothelial cells within the heart.
Claimed Compositions
- Nucleic Acid Molecules: The patent claims nucleic acid molecules encoding specific therapeutic proteins. Examples of such proteins include vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and nitric oxide synthase (NOS).
- Therapeutic Protein Encoding Genes: The claims cover DNA or RNA sequences that, when expressed, produce proteins beneficial for cardiovascular health. This can include genes that:
- Promote angiogenesis.
- Inhibit smooth muscle cell proliferation.
- Protect against ischemic damage.
- Improve cardiac contractility.
- Pharmaceutical Compositions: The patent also covers pharmaceutical compositions comprising the nucleic acid molecules, optionally formulated with a pharmaceutically acceptable carrier and a vector for delivery.
Table 1 summarizes key aspects of the claims:
| Claim Element |
Description |
| Objective |
Treat a cardiovascular disease in a subject. |
| Core Action |
Introduce a nucleic acid molecule into cardiac cells of the subject. |
| Nucleic Acid Encodes |
A therapeutic protein that promotes blood vessel growth. |
| Examples of Proteins |
Vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), nitric oxide synthase (NOS). |
| Examples of Diseases |
Myocardial infarction, angina, congestive heart failure, peripheral vascular disease. |
| Delivery Means |
Viral vectors, non-viral vectors (implied, not exclusive). |
| Target Cells |
Cardiac cells (cardiomyocytes, vascular endothelial cells within the heart). |
What is the prior art relevant to this patent?
The patent's prosecution history reveals several prior art references considered by the United States Patent and Trademark Office (USPTO). These references addressed various aspects of cardiovascular disease treatment and gene therapy, establishing the landscape against which the patent's novelty and inventiveness were assessed.
Key prior art categories include:
- Research on Angiogenesis Factors: Publications detailing the biological functions of growth factors like VEGF and FGF in promoting blood vessel formation.
- Gene Therapy for Other Diseases: Studies demonstrating the feasibility of gene delivery to various cell types for therapeutic purposes, even if not specifically for cardiovascular applications.
- Ischemic Heart Disease Pathophysiology: Scientific literature explaining the mechanisms of damage and blood flow reduction in conditions like myocardial infarction.
- Early Gene Therapy Delivery Methods: Reports on the development and application of viral and non-viral vectors for gene transfer.
Specific prior art references cited during examination (though not exhaustive of all relevant background literature) include publications related to the discovery and characterization of growth factors and their roles in tissue repair. The patent's claims were narrowed and refined to distinguish its asserted inventive steps from these existing disclosures.
What is the current patent landscape for cardiovascular gene therapy?
The patent landscape for cardiovascular gene therapy is extensive and dynamic, with numerous patents filed and granted since US Patent 5,827,721. This landscape reflects significant ongoing research and development efforts.
Key Trends in Cardiovascular Gene Therapy Patents:
- Therapeutic Targets: Patents increasingly focus on specific molecular targets and pathways beyond basic angiogenesis. This includes genes involved in cardiac regeneration, electrophysiology, and immune modulation.
- Delivery Systems: Innovations in delivery vectors are a major focus, with patents covering improved viral vectors (e.g., adeno-associated viruses with enhanced tropism and reduced immunogenicity), non-viral nanoparticles, and cell-based delivery systems designed for targeted and sustained gene expression.
- Therapeutic Indications: While US Patent 5,827,721 broadly covers cardiovascular disease, newer patents often specify indications such as specific types of heart failure, arrhythmias, or rare genetic cardiomyopathies.
- Combination Therapies: A growing area involves patents claiming combinations of gene therapies with small molecules, cell therapies, or biomaterials for synergistic effects.
- Manufacturing and Regulatory Pathways: Patents also emerge concerning scalable manufacturing processes for gene therapy products and strategies for navigating regulatory approvals.
Notable Patent Filings and Grants (Post-1998):
While a comprehensive list is beyond the scope of this analysis, significant patent activity involves:
- Companies: Major pharmaceutical and biotechnology companies such as Novartis, Pfizer, Amgen, and numerous smaller biotechs hold substantial portfolios in cardiovascular gene therapy.
- Academic Institutions: Leading research universities continue to patent novel gene therapy approaches.
- Specific Gene Targets: Patents are seen for gene therapies targeting pathways like PI3K/Akt, mTOR, and various transcription factors involved in cardiac function and repair.
The existence of US Patent 5,827,721 establishes an early foundation in the field, but the ongoing patenting of advancements in delivery, targets, and applications indicates a competitive and evolving intellectual property environment.
What are the potential challenges and limitations of this patent?
The enforceability and commercial viability of US Patent 5,827,721 may face several challenges and limitations, particularly given its issuance date and the advancements in the field since 1998.
Potential Challenges:
- Prior Art Discovery: Ongoing research may uncover additional prior art that predates the patent's filing date and anticipates or renders obvious the claimed inventions.
- Claim Interpretation: Broad claims can be subject to restrictive interpretations by courts, potentially limiting their scope. The precise meaning of terms like "cardiac cells" or "therapeutic protein" could be debated.
- Enablement and Written Description: The patent must adequately describe and enable one skilled in the art to practice the claimed invention. If the disclosure is deemed insufficient, challenges to validity can arise.
- Best Mode: The patentee must disclose the best mode contemplated for carrying out the invention. Failure to do so can lead to invalidity.
- Infringement Analysis: Proving infringement would require demonstrating that a competitor's product or method practices every element of at least one asserted claim. With evolving technologies, this can be complex.
Limitations:
- Technological Obsolescence: The specific gene delivery methods or therapeutic proteins disclosed may have been superseded by more effective or safer technologies developed since 1998.
- Scope of Claims: The claims may be narrowly drawn, leaving significant room for competitors to develop alternative approaches that do not infringe. For instance, if the claims are tied to specific viral vectors or gene sequences, advancements in other modalities would fall outside the patent's protection.
- Exclusivity Period: Patents have a finite term. US Patent 5,827,721, issued in 1998, is nearing the end of its 20-year term from the filing date, meaning it will eventually expire. The effective market exclusivity is further reduced by patent term adjustments and potential patent term extensions.
- Clinical and Regulatory Hurdles: The patent claims a method of treatment. Practical application requires successful clinical trials, regulatory approval, and market adoption, which are independent of patent validity and enforceability.
What is the commercial impact and licensing potential?
The commercial impact and licensing potential of US Patent 5,827,721 are significantly influenced by its age and the evolution of gene therapy for cardiovascular disease.
Commercial Impact:
- Foundational Intellectual Property: The patent represents an early foundational patent in the field of cardiovascular gene therapy. It likely contributed to establishing the intellectual property framework that encouraged further investment and research.
- Limited Direct Commercial Application Today: Given its issuance date and the rapid pace of scientific advancement, the patent's direct commercial application for novel therapies today is limited. Newer, more advanced gene therapy platforms and targets have emerged, often protected by more recent patents.
- Potential for Retroactive Licensing Claims: If The Johns Hopkins University or its licensees have been actively developing and commercializing therapies covered by this patent, there could have been past licensing agreements or potential claims for infringement against commercial products that emerged during its active term. However, identifying such products and substantiating infringement for a patent of this age requires extensive investigation.
Licensing Potential:
- Expired Patents: As of late 2023, the patent term for US Patent 5,827,721 would have expired approximately in late 2018 (20-year term from filing date, assuming a 1998 filing date, though the issue date is Oct 27, 1998, the effective filing date would be earlier). Therefore, its licensing potential for new commercial development is effectively zero as it is in the public domain.
- Historical Significance: While not licensable for future use, the patent holds historical significance as a testament to early innovation in the field. Its existence would have been a factor in licensing negotiations during its active term.
- Cross-licensing and Freedom to Operate: During its active period, the patent would have been a critical consideration for companies seeking to operate in the cardiovascular gene therapy space. It may have necessitated cross-licensing agreements to secure freedom to operate.
The value of this patent today lies more in its historical context and the precedents it may have set in patent law and scientific understanding rather than its direct commercial or licensing utility.
Key Takeaways
- US Patent 5,827,721, issued in 1998, claims gene therapy methods for cardiovascular disease by introducing nucleic acid molecules encoding therapeutic proteins that promote blood vessel growth into cardiac cells.
- The patent's core innovation involves the application of gene therapy to address conditions such as myocardial infarction and angina through induced angiogenesis.
- The patent landscape for cardiovascular gene therapy is highly active and competitive, with numerous patents filed and granted since 1998, focusing on advanced delivery systems, specific molecular targets, and refined therapeutic indications.
- Potential challenges to the patent's enforceability and utility include the discovery of prior art, claim interpretation disputes, and the inherent limitations of its age, including approaching patent expiration.
- Given its issuance date, US Patent 5,827,721 has expired, rendering it unable to be licensed for new commercial development. Its primary impact is now historical, reflecting early foundational work in cardiovascular gene therapy.
Frequently Asked Questions
-
When did US Patent 5,827,721 expire?
The patent term for US Patent 5,827,721 would have expired approximately in late 2018, based on its 20-year term from the filing date.
-
Can I freely use the technology described in US Patent 5,827,721 now?
Yes, as the patent has expired, the technology described within its claims is now in the public domain and can be used freely without requiring a license.
-
What specific types of cardiovascular diseases are covered by the patent?
The patent broadly covers cardiovascular diseases including, but not limited to, myocardial infarction, angina, congestive heart failure, and peripheral vascular disease.
-
Does the patent claim specific viral vectors for gene delivery?
The patent claims methods for introducing nucleic acid molecules and contemplates the use of various delivery means, but it is not exclusively limited to specific viral vectors. It encompasses the concept of gene introduction into cardiac cells.
-
Are there any ongoing legal disputes related to US Patent 5,827,721?
Due to the patent's expiration, ongoing legal disputes regarding its infringement are highly unlikely. Such disputes would typically occur during the active patent term.
Citations
[1] United States Patent 5,827,721. (1998). Gene therapy for cardiovascular disease. The Johns Hopkins University.
More… ↓
⤷ Start Trial
|
